Showing results (191-200 of 697) with videos related to

Sort By:
Pageof 70
Blood Advances|June 25, 2026
Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System InvolvementAlexander Xiao, Saurabh S Zanwar, Yi Lin, et al.
Blood|October 13, 2016
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatmentEli Muchtar, Dragan Jevremovic, Angela Dispenzieri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2018
Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple MyelomaAnkit Kansagra, Wilson I Gonsalves, Morie A Gertz, et al.
Leukemia|September 28, 2025
Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysisSaurabh Zanwar, Gokce Belge Bilgin, Stephen M Broski, et al.
The New England Journal of Medicine|July 15, 2026
Continuous or Fixed-Duration Maintenance Therapy in Multiple MyelomaShaji Kumar, Susanna Jacobus, Adam Cohen, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 4, 2020
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma PatientsAbdullah S Al Saleh, Harsh V Parmar, Alissa Visram, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 26, 2015
Bortezomib-induced acute interstitial nephritisWisit Cheungpasitporn, Nelson Leung, S Vincent Rajkumar, et al.
Cancer|February 28, 2009
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93Robert A Kyle, Susanna Jacobus, William R Friedenberg, et al.
Plos One|November 28, 2012
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathwayVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|February 14, 2017
Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the LiteratureAlex D Sweeney, Jacob B Hunter, S Vincent Rajkumar, et al.
Pageof 70